Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Doma Biopharmaceutical’s Bispecific ADC DM001 Receives FDA Clearance for Clinical Trial

Fineline Cube Jul 5, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-9813 IPF Clinical Trial

Fineline Cube Jul 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management

Fineline Cube Jul 5, 2024

Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...

Company Drug R&D

Semaglutide Use Linked to Rare Eye Condition NAION in New Study

Fineline Cube Jul 5, 2024

A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...

Company Drug

J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients

Fineline Cube Jul 5, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...

Company Drug

Sanofi’s RSV Preventative Therapy Beyfortus Launches in China

Fineline Cube Jul 4, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...

Company Deals

Genertec and CTHG Fund Invest in Neusoft Medical Systems to Boost Medical Imaging

Fineline Cube Jul 4, 2024

China General Technology (Group) Holding Co Ltd, commonly referred to as Genertec, has announced plans...

Company Deals

Guangzhou Pluslife Partners with Gates Foundation to Combat STIs in Low-Income Countries

Fineline Cube Jul 4, 2024

Guangzhou Pluslife Technology Co., Ltd, a specialist in Point-Of-Care Testing (POCT) based in China, has...

Company Deals

United Imaging Healthcare to Launch Financial Leasing Arm with RMB 450 Million Investment

Fineline Cube Jul 4, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical equipment company based in Shanghai, has...

Company Deals

Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda

Fineline Cube Jul 4, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Full-Life Technologies’ ²²⁵Ac-FL-020 Earns FDA Fast-Track Status for mCRPC

Fineline Cube Jul 4, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Drug

HutchMed’s Tazverik for Follicular Lymphoma Accepted for Review by China’s NMPA

Fineline Cube Jul 4, 2024

HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced that the National Medical Products Administration...

Company Medical Device

Blue Sail Medical’s Fastroad Catheter Earns NMPA Marketing Approval

Fineline Cube Jul 4, 2024

Blue Sail Medical Co., Ltd (SHE: 002382), a medical device company based in China, has...

Company

Philips Appoints Liu Ling as Greater China President Amid Leadership Changes

Fineline Cube Jul 4, 2024

Dutch multinational Philips has appointed Liu Ling as President of Greater China, effective immediately. Liu...

Company Deals

CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China

Fineline Cube Jul 4, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement...

Company Deals

Amgen Secures Commercialization Rights for Avacopan in Asia and Latin America

Fineline Cube Jul 4, 2024

Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, has entered into a licensing agreement with CSL...

Company Deals

GSK Secures Global Rights to CureVac’s mRNA Vaccine Candidates in Expanded Partnership

Fineline Cube Jul 4, 2024

GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership...

Company Deals

China’s HiRO Expands US Presence with Acquisition of New Jersey-Based DeltaMed Solutions

Fineline Cube Jul 4, 2024

Harvest Integrated Research Organization (HiRO), a China-based ’boutique’ Contract Research Organization (CRO), has expanded its...

Company Drug

LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China

Fineline Cube Jul 4, 2024

LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd...

Company Drug

AstraZeneca’s Voydeya Receives South Korean Approval for PNH Treatment

Fineline Cube Jul 4, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has reportedly secured market approval in South...

Posts pagination

1 … 388 389 390 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.